Breakthrough in cell-based assay development

29 April 2008

US company MaxCyte has introduced the ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology. The system enables rapid and efficient transfection of any kind of cell or cell line with any molecule (plasmids, proteins, protein complexes, drugs, mRNA, siRNA), at scales ranging from micro-litres to litre volumes.

MaxCyte's ITF Inline Transfection System enables transient transfection of cell lines as well as primary cells, and is now available for drug discovery and screening applications. The sterile, closed system provides consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods.

Many cell based assays and research projects are based on recombinant cell lines. Optimizing such cell lines so they express a desired set of properties and are compatible with a particular screening platform takes considerable time and expense. Because of its ease and speed, transient transfection is increasingly used to replace cloning and recombinant work in a wide range of applications (eg ion channel-based drug or GPCR screening).

The MaxCyte ITF Inline Transfection system replaces current preparative transfection technologies which depend on expensive and complicated virus constructs, lipid-based transfection agents, or small scale electroporation devices.

To top